434 related articles for article (PubMed ID: 17601603)
1. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
[TBL] [Abstract][Full Text] [Related]
2. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation.
Blumenfeld Z; Patel B; Leiba R; Zuckerman T
Fertil Steril; 2012 Nov; 98(5):1266-70.e1. PubMed ID: 22935556
[TBL] [Abstract][Full Text] [Related]
4. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients.
Huser M; Crha I; Ventruba P; Hudecek R; Zakova J; Smardova L; Kral Z; Jarkovsky J
Hum Reprod; 2008 Apr; 23(4):863-8. PubMed ID: 18258763
[TBL] [Abstract][Full Text] [Related]
5. Prevention of gonadal damage during cytotoxic therapy.
Blumenfeld Z; Haim N
Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
[TBL] [Abstract][Full Text] [Related]
6. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy.
Castelo-Branco C; Nomdedeu B; Camus A; Mercadal S; Martínez de Osaba MJ; Balasch J
Fertil Steril; 2007 Mar; 87(3):702-5. PubMed ID: 17173900
[TBL] [Abstract][Full Text] [Related]
7. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a.
Blumenfeld Z; Eckman A
J Natl Cancer Inst Monogr; 2005; (34):40-3. PubMed ID: 15784821
[TBL] [Abstract][Full Text] [Related]
8. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report.
Pereyra Pacheco B; Méndez Ribas JM; Milone G; Fernández I; Kvicala R; Mila T; Di Noto A; Contreras Ortiz O; Pavlovsky S
Gynecol Oncol; 2001 Jun; 81(3):391-7. PubMed ID: 11371127
[TBL] [Abstract][Full Text] [Related]
9. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Blumenfeld Z
Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
[TBL] [Abstract][Full Text] [Related]
10. GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients.
Nitzschke M; Raddatz J; Bohlmann MK; Stute P; Strowitzki T; von Wolff M
Arch Gynecol Obstet; 2010 Jul; 282(1):83-8. PubMed ID: 19967405
[TBL] [Abstract][Full Text] [Related]
11. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
12. GnRH analogue for chemotherapy-induced ovarian damage: too early to say?
Peccatori F; Demeestere I
Fertil Steril; 2009 Aug; 92(2):e33; author reply e34. PubMed ID: 19646600
[No Abstract] [Full Text] [Related]
13. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
[TBL] [Abstract][Full Text] [Related]
14. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
[TBL] [Abstract][Full Text] [Related]
15. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.
Blumenfeld Z; von Wolff M
Hum Reprod Update; 2008; 14(6):543-52. PubMed ID: 18824495
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: a mouse model.
Tan SJ; Yeh YC; Shang WJ; Wu GJ; Liu JY; Chen CH
Eur J Obstet Gynecol Reprod Biol; 2010 Apr; 149(2):182-5. PubMed ID: 20074846
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
18. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy.
Franke HR; Smit WM; Vermes I
Gynecol Endocrinol; 2005 May; 20(5):274-8. PubMed ID: 16019373
[TBL] [Abstract][Full Text] [Related]
19. GnRH-agonists in fertility preservation.
Blumenfeld Z
Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):523-8. PubMed ID: 18971681
[TBL] [Abstract][Full Text] [Related]
20. Inhibin A concentrations in the sera of young women during and after chemotherapy for lymphoma: correlation with ovarian toxicity.
Blumenfeld Z; Ritter M; Shen-Orr Z; Shariki K; Ben-Shahar M; Haim N
Am J Reprod Immunol; 1998 Jan; 39(1):33-40. PubMed ID: 9458932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
